More on FRX
Data
Financials
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $12.00 |
|
|||
| Open | $24.87 | ||||
| 52 Wk High | $100.88 | ||||
| 52 Wk Low | $64.33 | ||||
| Day High | $12.00 | ||||
| Day Low | $12.00 | ||||
| P/E | 20.69 | ||||
| EPS | $0.58 | ||||
| Volume | 20 | ||||
- Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
- Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
- Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
- Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
- Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Form 8-K FENNEC PHARMACEUTICALS For: Mar 16
- Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation
- Form 4 FENNEC PHARMACEUTICALS For: Feb 18 Filed by: Andrade Robert
Entities mentioned with FRX
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Carl Icahn | View Related Stories »
- Needham & Company | View Related Stories »
- Morgan Stanley | View Related Stories »
- UBS | View Related Stories »
- Cantor Fitzgerald | View Related Stories »
- Show More...
